Analysis of Mesenchymal Stromal Cell Engraftment After Allogeneic HSCT in Pediatric Patients: A Large Multicenter Study

Laura M Castello, Marco Leone, Aloe Adamini, Sara Castiglia, Katia Mareschi, Ivana Ferrero, De Gobbi Marco, Fabrizio Carnevale-Schianca, Franca Fagioli, Massimo Berger

Research output: Contribution to journalArticlepeer-review

Abstract

The mesenchymal stem cell (MSC) role after allogeneic hematopoietic stem cell transplantation (HSCT) is still a matter of debate; in particular, MSC engraftment in recipient bone marrow (BM) is unclear. A total of 46 patients were analyzed for MSC and hemopoietic stem cell engraftment after HSCT. The majority of patients had the BM as the stem cell source, and acute leukemia was the main indication for HSCT. Mesenchymal and hematopoietic stem cell chimerism analysis was carried out through specific polymorphic tandemly repeated regions. All patients reached complete donor engraftment; no evidence of donor-derived MSC engraftment was noted. Our data indicate that MSCs after HSCT remain of recipient origin despite the following: (i) myeloablative conditioning; (ii) the stem cell source; (iii) the interval from HSCT to BM analysis; (iv) the underlying disease before HSCT; and (v) the patients' or the donors' age at HSCT.

Original languageEnglish
Pages (from-to)e486-e489
JournalJournal of Pediatric Hematology/Oncology
Volume40
Issue number8
DOIs
Publication statusPublished - Nov 2018

Fingerprint

Dive into the research topics of 'Analysis of Mesenchymal Stromal Cell Engraftment After Allogeneic HSCT in Pediatric Patients: A Large Multicenter Study'. Together they form a unique fingerprint.

Cite this